BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32:3347-3348. [PMID: 25154828 DOI: 10.1200/jco.2014.57.5597] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Jakuboski S, Doyle T, Tawa M, Fisher DC, Leboeuf N, Larocca C. Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient. Curr Derm Rep. [DOI: 10.1007/s13671-022-00367-4] [Reference Citation Analysis]
2 Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022. [PMID: 35589997 DOI: 10.1038/s41409-022-01691-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
3 Yonekura K. Current treatment strategies and emerging therapies for cutaneous lymphoma. J Dermatol 2021. [PMID: 34958516 DOI: 10.1111/1346-8138.16289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kim YH. What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology Am Soc Hematol Educ Program 2021;2021:303-12. [PMID: 34889422 DOI: 10.1182/hematology.2021000263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Franke G, Dumann K, Jentzsch M, Monecke A, Doehring C, Nehring-vucinic C, Schwind S, Niederwieser D, Platzbecker U, Ziemer M, Vucinic V. Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome. Front Oncol 2021;11:749691. [DOI: 10.3389/fonc.2021.749691] [Reference Citation Analysis]
6 Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, Nikolaou V, Pappa V, Papadavid E, Tsirigotis P. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. Clin Hematol Int 2021;3:72-6. [PMID: 34595469 DOI: 10.2991/chi.k.210529.001] [Reference Citation Analysis]
7 Sanches JA, Cury-Martins J, Abreu RM, Miyashiro D, Pereira J. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario. An Bras Dermatol 2021;96:458-71. [PMID: 34053802 DOI: 10.1016/j.abd.2020.12.007] [Reference Citation Analysis]
8 Dodero A, Corradini P. Allogeneic Stem‐cell Transplantation. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch23] [Reference Citation Analysis]
9 García-Díaz N, Piris MÁ, Ortiz-Romero PL, Vaqué JP. Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers (Basel) 2021;13:1931. [PMID: 33923722 DOI: 10.3390/cancers13081931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
10 de Masson A, Peffault de Latour R, Ram-wolff C, Bagot M. Traitement des lymphomes T cutanés par allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:187-192. [DOI: 10.1016/j.fander.2020.07.004] [Reference Citation Analysis]
11 Walker CJ, Donnelly ED, Moreira J, Mehta J, Mittal BB, Choi J, Zhou XA, Guitart J, Pro B. Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides. JAAD Case Rep 2021;7:87-90. [PMID: 33344742 DOI: 10.1016/j.jdcr.2020.10.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
13 Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
15 Dimitriou F, Schanz U, Nair G, Kimeswenger S, Brüggen MC, Hoetzenecker W, French LE, Dummer R, Cozzio A, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. Front Med (Lausanne) 2020;7:290. [PMID: 32714935 DOI: 10.3389/fmed.2020.00290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am 2019;33:103-20. [PMID: 30497668 DOI: 10.1016/j.hoc.2018.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
17 Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ. Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma? Curr Oncol Rep 2019;21:65. [PMID: 31183579 DOI: 10.1007/s11912-019-0809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Leuchte K, Schlaak M, Stadler R, Theurich S, von Bergwelt-baildon M. Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom. Kompass Dermatol 2019;7:111-119. [DOI: 10.1159/000500890] [Reference Citation Analysis]
19 Arslan S, Hosing C. Hematopoietic Stem Cell Transplantation for Rare Hematological Malignancies. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00019-5] [Reference Citation Analysis]
20 Bhat T, Zwerner JP, Musiek A. Cutaneous Lymphomas. A Practical Guide to Skin Cancer 2018. [DOI: 10.1007/978-3-319-74903-7_8] [Reference Citation Analysis]
21 Epperla N, Hamadani M, Horowitz MM. Indications for Allogeneic Hematopoietic Stem Cell Transplantation in Adults. Establishing a Hematopoietic Stem Cell Transplantation Unit 2018. [DOI: 10.1007/978-3-319-59358-6_7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 van Santen S, Vermeer MH, Willemze R. Classification and recommended treatment options for folliculotropic mycosis fungoides. Expert Opinion on Orphan Drugs 2017;6:35-45. [DOI: 10.1080/21678707.2018.1406796] [Reference Citation Analysis]
23 Berg S, Villasenor-Park J, Haun P, Kim EJ. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome. Curr Hematol Malig Rep 2017;12:234-43. [PMID: 28540671 DOI: 10.1007/s11899-017-0387-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Stranzenbach R, Theurich S, Schlaak M. [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma]. Hautarzt 2017;68:716-20. [PMID: 28785925 DOI: 10.1007/s00105-017-4023-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
25 Hoppe RT, Kim YH, Advani RH. Mycosis Fungoides and Sézary Syndrome. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm121] [Reference Citation Analysis]
26 Khan Mohammad Beigi P. Treatment. Clinician's Guide to Mycosis Fungoides 2017. [DOI: 10.1007/978-3-319-47907-1_6] [Reference Citation Analysis]
27 Hanel W, Briski R, Ross CW, Anderson TF, Kaminski MS, Hristov AC, Wilcox RA. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am J Hematol 2016;91:E491-5. [PMID: 27649045 DOI: 10.1002/ajh.24564] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
28 Ma H, Abdul-Hay M. T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol 2017;22:18-51. [PMID: 27743148 DOI: 10.1007/s10147-016-1045-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
29 Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res 2016;47:100-8. [PMID: 27294334 DOI: 10.1016/j.leukres.2016.05.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
30 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
31 Pullarkat V, Forman SJ. Hematopoietic Cell Transplantation for Rare Hematologic Malignancies. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Bailey NG, Elenitoba-Johnson KS. Mature T-cell leukemias: Molecular and Clinical Aspects. Curr Hematol Malig Rep 2015;10:421-8. [PMID: 26433891 DOI: 10.1007/s11899-015-0288-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 2015;26:2490-5. [PMID: 26416896 DOI: 10.1093/annonc/mdv473] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
34 Jacobsen ED. Stem cell transplantation for mycosis fungoides/Sézary syndrome. Clinical Guide to Transplantation in Lymphoma 2015. [DOI: 10.1002/9781118863282.ch23] [Reference Citation Analysis]
35 Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50:1037-56. [PMID: 25798672 DOI: 10.1038/bmt.2015.6] [Cited by in Crossref: 218] [Cited by in F6Publishing: 237] [Article Influence: 27.3] [Reference Citation Analysis]
36 Panchal MR, Scarisbrick JJ. The utility of bexarotene in mycosis fungoides and Sézary syndrome. Onco Targets Ther 2015;8:367-73. [PMID: 25678803 DOI: 10.2147/OTT.S61308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]